INTRODUCTION
HIV and Hepatitis C (HCV) infection are major global public health concerns, with overlapping modes of transmission and affected populations. As of December 2014, an estimated 36.9 million people were living with HIV, 2·3 million were newly infected and 1·6 million died.
1 While HIV transmission has declined since 2001, with improved survival due to the scale-up of anti-retroviral therapies (ART), more people are living with HIV than ever before. 2 It was estimated that in 2005 over 184 million people were HCV antibody positive. 3 More recent data suggest this has declined to 115 million (92-149) 4 , with this being attributed to improved screening of blood supply, decreases in injecting risk behaviours and differences in prevalence reported from South East Asia. However, other evidence 5 6 suggests the disease burden remains high, with 3-4 million new infections and 350,000 deaths occurring annually. 3, 7 HCV treatment has been transformed with the advent of direct acting antivirals (DAAs) which offer high cure rates within 12-24 weeks. 8 The interaction between HIV and HCV co-infection impacts on the transmission and natural history of HCV infection. The transmission efficiency of HCV increases in the presence of HIV infection, with the perinatal transmission risk doubling among HIV-infected mothers. 9, 10 People living with HIV (PLHIV) without treatment are less likely to spontaneously clear HCV infection, have higher HCV viral loads and experience more rapid HCV disease progression than those without HIV infection. 11 Although ART improves outcomes in HCV co-infected patients, with decreased HCV-related mortality, 12 HCV co-infection may also complicate HIV treatment, with some evidence suggesting an increased risk of drug-related hepatoxicity among those on ART. 12 There remains a lack of consistent data on the impact of HCV co-infection on HIV progression. 13 9, 12 As PLHIV live longer, HCV-related liver disease in co-infected patients is becoming a major cause of morbidity and mortality. However, the burden of HIV-HCV co-infection is poorly understood. One review suggested 4-5 million PLHIV are infected with HCV 14 , but relied on a small number of studies and unclear methodologies, while a second reported prevalence from selected studies only. 15 Other reviews have provided estimates for sub-Saharan Africa only 16 17 or among people who inject drugs (PWID) 18 , but there have been no reviews documenting the global burden of HCV co-infection among PLHIV. Reliable estimates are needed to determine the scale of the public health problem posed by HCV co-infection and to inform regional and national strategies for hepatitis screening and management. [19] [20] [21] [22] [23] We therefore undertook a systematic review to estimate the prevalence and global burden of HCV co-infection among PLHIV.
METHODS

Search strategy and selection criteria
We searched eight databases for material that reported the prevalence of HCV and HIV, published between 2002 and 2015, following the PRISMA guidelines. 24 The searches were done in January 2015 in MEDLINE, EMBASE, CINAHL+, POPLINE, Africa-wide Information, Global Health, Web of Science, and the Cochrane Library, Index Medicus of the Eastern Mediterranean Region, Index Medicus of the South-East Asian Region, LILACS and Western Pacific Region Index Medicus. All language sources were included. Search terms included: 'HIV OR Human immunodeficiency virus' and 'OR Hepatitis-C OR HCV' and 'prevalen* OR inciden* OR seroprevalen* OR screening OR surveillance OR population* OR survey* OR epidem* OR data collection OR population sample* OR community survey* OR cohort OR cross-sectional OR longitude* OR follow-up'. Searches were tailored to each database. Reference lists were screened for additional sources.
We included papers with estimates of HCV co-infection among HIV population samples greater than 50, recruited based on HIV infection status or other behavioural characteristic. We excluded editorials or reviews containing no primary data, samples of HCV or HIV/HCV infected individuals, or samples relying on self-reported infection status. We excluded samples drawn from populations with other co-morbidities or undergoing interventions that put them at greater risk of co-infection.
Screening and data extraction
Two reviewers (CM, BM) screened all sources for inclusion, with a third reviewer (LP) consulted when necessary. Data extracted included: study methods; field-work dates; population sampled; recruitment site; sample size; diagnostic assays used; and prevalence of co-infection. For 10% of included studies, data were double extracted by a second author (EG) to check for accuracy.
Quality assessment
Studies were rated according to their study design and assay quality (Appendix, Box 1). Studies with larger sample sizes, recruited from multiple sites, recording age, sex or HIV risk-factors were scored higher (A) and lower scores (C) were given if none were reported. HCV antibody assay methods were rated from 0 where no assay type was specified, up to 3 when they used a 2 nd or 3 rd generation HCV antibody assay with confirmatory testing. Best estimates were selected for each population group per country based on the highest study design and assay score. Where multiple estimates existed, we applied decision rules to select the best estimate (Appendix Box 2).
Classification of countries according to Global Burden of Disease region
Countries were grouped according to the 21 Global Burden of Disease regions, consistent with previous published reviews on HCV burden.
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Definition of Population groups Populations were categorised according to their main HIV exposure categories. General population samples were considered low-risk, and included samples of blood donors (unpaid), ante-natal clinic attendees or general population surveys, not recruited based on HIV positive status. Samples of PLHIV reporting heterosexual transmission as the main risk factor or pregnant women were grouped together. We categorised samples as PWID when >75% of individuals had experience of injecting, and as men who have sex with men (MSM) when >75% reported main HIV exposure to be sex with men. These two groups included studies of PLHIV and populations recruited based on risk behaviour. Other population groups included: PLHIV reporting any injecting drug use (but <75% had experience of injecting); sex workers; prison inmates; drug users (non-injecting); high-risk (recruited from STI clinics or a mixed population engaging in sexual and/or injecting risk behaviours but <75% had experience of injecting).
Data synthesis
We reported HIV/HCV co-infection prevalence among four population groups by country and region, reporting the best estimate and range for each country. Global and regional prevalence estimates were derived from the median of the 'best' estimates for that region with the inter-quartile range (IQR). Data were entered into ArcGIS 10·2 (Environmental Systems Research Institute, Redlands, CA.) to generate maps presenting country-level HIV/HCV co-infection prevalence estimates.
We synthesised estimates across six independent population groups (general population, PWID, MSM, sex workers, prison inmates and high-risk populations) on overall HCV co-infection and monoinfection prevalence, and undertook a meta-analysis across the 'best' estimates of the odds of being HCV-positive among HIV-positive populations compared to HIV-negative populations, stratified by population group. A standard correction of 0·5 was added to all zero prevalence estimates using STATA 13·1 (Stata Corp, College Station, Tex). Odds ratios were calculated through a MantelHaenszel method with a random-effect model. Meta-analysis are presented as forest plots.
We report global and regional estimates of burden of HCV co-infection among PLHIV. Using number of PLHIV by country and region estimated by the Joint United Nations Programmes on HIV/AIDS (UNAIDS) 1 , we applied the median HCV co-infection prevalence among PLHIV for non-PWID samples from the literature search for MSM, general population and HIV-positive samples of pregnant women or those heterosexually exposed by sub-regions and then overall. The HCV prevalence among HIV-positive PWID was also applied to the distribution of HIV-positive PWID across subregions, as estimated by UNAIDS.
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Role of the funding source The WHO commissioned this review to inform the update of the WHO guidelines on screening of coinfections and initiation of ART. The funder contributed to the data collection, analysis, interpretation, and writing of the review. All authors had full access to the study data and share final responsibility for the findings submitted for publication.
RESULTS
From a total of 31,767 publication references, 783 papers met the inclusion criteria resulting in 902 estimates of the prevalence of HIV/HCV co-infection ( Figure 1 ).
Availability of estimates by region
Co-infection estimates were identified for 89 of the 194 countries (46%). In Sub Saharan African, the most estimates were identified in East Africa (11/15), then South Africa (4/6), and fewest in Central and West Africa (9/24). A total of seven estimates were identified in North Africa and the Middle East (7/21). Estimates were found in every country in North America (n=2) but the minority of countries in South America (8/21) and the Caribbean (3/15). Estimates were identified in 8 countries in South and South East Asia (8/17), three countries in Asia Pacific and Australasia (n=17), and one in East Asia (n=2). Across Europe, a total of 9 estimates were identified in Eastern European (9/12) and Central Asian countries, 18 in Western (18/24) and 5 in Central European countries (5/12).
Prevalence of HIV/HCV co-infection
General population samples
The mid-point prevalence of HCV co-infection among 30 HIV-infected general population samples was 2.4% (IQR 0·8-5·8%). The highest prevalence was in North Africa and the Middle East (5.8%) and the lowest prevalence in East Africa (0.6%). Within these general population samples, prevalence was highest among blood donors at >10% in India and Nepal, and 7% in Brazil. [27] [28] [29] [30] All estimates are summarised in Table 1 .
PLHIV (heterosexual and pregnant women)
The mid-point prevalence of HCV co-infection among 95 studies in PLHIV (heterosexual /pregnant women) was 4·0% (IQR 1·2-8·4%). Prevalence was highest in West and Central Africa (9·0%, IQR 8·0-11·0) and lowest in Southern Africa (0·5%, IQR 0-1·0%).
MSM
The mid-point prevalence among 80 MSM samples was 6·4% (IQR 3·2-10·0%). Prevalence was highest in North America (16·2%, IQR= 15·2-17·3%) and lowest in East Asia and South and South East Asia (2·0%).
PWID
The mid-point prevalence among 123 studies of PWID (≥75% of sample ever PWID) was 82·4% (IQR 55·2-84·5%) with little regional variation. The highest prevalence was in North Africa/Middle East (88·5%) and lowest in Western and Central Europe (69·9% and 58·5% respectively). There were a further 333 estimates from samples of PLHIV, where injecting drug use was a key exposure but <75% of the sample injected drugs. Among these estimates, the median prevalence of injecting drug use was 29·0% (IQR 13·9-46·%). There was a clear association between the prevalence of self-reported injecting drug use and HIV/HCV co-infection prevalence (Figure 3 -correlation coefficient 0·89, p<0.001).
Odds of HCV infection among HIV-positive relative to HIV-negative persons
Across all population groups, there was a 5·8-fold (95% CI 4·5-7·5) increased odds of HCV positivity among HIV-positive compared to HIV-negative persons, but with high heterogeneity (I squared 95·7%, p<0·001). Odds of HCV were highest among HIV-positive prison inmates (OR=17·4, 95%CI 7·6-39·5), but comparable among MSM (OR=7·5 95% CI 4·4-12·7), PWID (OR=6·0, 95%CI 4·2-8·7) and other high-risk populations (OR=6·8 95%CI 4·0-11·5), then lowest among sex workers (OR=3·1, 95%CI 1·4-6·8) and general population samples (OR=1·6, 95% CI 1·0-2·5). Within study heterogeneity was high for all population groups except for general population and sex-worker samples where it was moderate. See Figure 4 and Online Table 2 .
Global burden of HCV co-infection among PLHIV
We estimate that there are 2,278,400 (IQR=1,271,300-4,417,000) cases of HCV co-infection among PLHIV globally, of which 1,362,700 (IQR=847,700-1,381,800) are among HIV-positive PWID. This gives a global prevalence of HCV co-infection among PLHIV of 6·2% (IQR 3·4-11·9%). Eastern Europe and Central Asia has the largest burden, representing 27% of the total, reflecting the large population of PWID (Table 2) .
DISCUSSION
This is the first global systematic review of the prevalence and burden of HCV among HIV infected persons. We estimate 2·3 million (IQR 1·3-4·4 million) cases of HCV co-infection among PLHIV globally, making a global prevalence of 6·2%, of whom 59% are PWID. The greatest burden is in Eastern Europe and Central Asia, due to the large HIV-infected population of PWID, where an estimated 607,700 HIV infected persons are co-infected with HCV infection, followed by 429,600 in Sub Saharan Africa. Prevalence of HCV co-infection among HIV-infected populations varies widely and is highest among PWID (82·4%, 55·2-88·5%), then MSM (6·4%, 3·2-10·0%) and pregnant or heterosexually exposed populations (4·0%, 1·2-8·4%), and lowest among general population samples (2·4%, 0·8-5·8%).
Findings corroborate previous evidence that South Asia, East Asia and Eastern Europe constitute the largest populations of anti-HCV infections. 3, 4 We found clear geographic differences in estimated HIV/HCV prevalence across population groups. Among general population samples, prevalence was highest in South America (3·9%) and West and Central Africa (3·6%) and lowest in East Africa (0·6%). Among HIV-positive pregnant women or those with heterosexual exposure, prevalence was again highest in West and Central Africa (9%), but lower in the rest of Sub-Saharan Africa. Previous reviews of HIV/HCV co-infection in Sub-Saharan Africa found a prevalence of between 5·7% and 7% among HIV positive cohorts, which is within the range of our estimates. 16 17 One of these reviews also reported comparably high rates of HCV co-infection in West Africa, but higher rates in South and East Africa than our review. A lack of data on risk behaviours made comparison of these regional differences challenging. 17 Among PWID, HIV/HCV co-infection prevalence is higher than 80% in six regions, particularly in regions where there are large populations of PWID with concentrated HIV epidemics, including Central and Eastern Europe, South and South East Asia and North America.
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PWID
This global review corroborates other evidence showing the importance of injecting drug use in driving the HCV epidemic among PWID and PLHIV, and that the highest burden of HCV among PWID is in the Russian Federation and China. 25, 32 We found a six-fold increased odds of HCV infection among HIV positive compared to HIV negative PWID population groups. This is consistent with parenteral transmission being the primary mode of HIV and HCV acquisition among PWID, and HCV being much more easily transmitted than HIV. 33 These findings highlight the urgent need to scale-up HIV and HCV prevention interventions among PWID including needle/syringe exchange programmes, opiate substitution therapy and provision of ART, both globally and specifically in Eastern Europe and South East Asia. 34 In addition, the new era of highly curative short course direct acting antiviral therapies for HCV offer the potential to not only improve individual clinical outcomes but also reduce transmission, 35 and therefore emphasises the importance of ensuring equitable access of PWID to HCV testing and DAA treatment.
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MSM
Overall, there was moderate HCV co-infection among HIV-positive MSM samples with an eight-fold increased odds of HCV infection in HIV-infected MSM compared to HIV-uninfected MSM. This data aligns well with growing evidence suggesting MSM are increasingly vulnerable to HCV transmission, in part fuelled by the use of new psychoactive substances, increased sexual and injecting risk and sero-sorting within this risk group. 36, 37 Evidence also suggests high rates of HCV re-infection following spontaneous clearance or treatment among HIV-positive MSM highlighting the need for repeated testing and targeted interventions among this population.
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Data limitations
Despite a systematic search of published and unpublished literature, estimates were only identified in 46% of countries globally, with few country-level estimates among general population samples. The study quality was variable highlighting the need for more robust monitoring of HCV among PLHIV, and increased transparency in the methodologies used as well as availability of estimates to facilitate monitoring of global trends. The higher co-infection prevalence among blood donors clearly shows the need for careful screening of blood donations for HCV and highlights the problems in inferring general population prevalence from this population. [27] [28] [29] [30] Given this potential bias, it is possible that our general population estimate for co-infection is an over-estimate, although it falls within the range published in previous regionally-focussed reviews and estimates are consistently lower than for other groups engaging in higher-risk behaviours. Higher prevalence among blood donors were observed in studies conducted prior to 2008 than more recent studies, indicative of improved screening of donors. 17 28, 39-41 The high level of within-study heterogeneity within our meta-analysis urge some caution in our interpretation of the impact of HIV positivity on odds of HCV infection particularly for prison inmates where the confidence intervals are wide, PWID and high-risk populations.
Our global review focussed on published literature and did not include an exhaustive review of grey literature, as applied in other systematic reviews of this kind 42 , though the inclusion of WHO databases and Global Health captured some unpublished grey literature. We lastly acknowledge that our focus on HCV antibody prevalence fails to fully determine the burden of active HCV infections among PLHIV (determined by HCV RNA positivity). Only 10% (92) of our estimates contained data on HCV RNA, the majority of which (47%) were derived from studies in North America or Western Europe. It is estimated that between 20-30% of those exposed to HCV antibodies will spontaneously clear the virus and be HCV RNA negative but remain antibody positive and this may differ across populations. 43, 44 Given the paucity of data and diversity in geographic regions, populations and risk groups covered in the review we considered that a focus on antibody prevalence better reflects the epidemiology of exposure and infection.
Conclusion
International guidelines recommend HCV screening for PLHIV in many settings, and provision of appropriate HCV care for those chronically infected. [19] [20] [21] [22] [23] However, this is currently poorly implemented, particularly in low and middle income settings, and among populations such as PWID, prisoners, sex workers and MSM. 32, 45 There is a clear mandate to prioritise screening of blood donors and routine testing of HCV among all PLHIV, but targeted approaches are needed for PWID and MSM where the magnitude of HCV infection risk has not been met with a commensurate investment in surveillance, testing and treatment. There is also a need to improve country-level data on prevalence of HCV among all populations to help them define their epidemiology and inform policies for hepatitis C testing, prevention, care and treatment. This is particularly important in countries with growing populations of PWID and concentrated HIV epidemics among PWID and MSM, but also in Sub-Saharan Africa where the burden of co-infection is large due to the high burden of HIV. This will need investment in building HCV surveillance and care and treatment capacity.
Research in context
Previous reviews of HIV/HCV co-infection have focussed on specific regions or sub-populations or not employed systematic review methodologies to extract and synthesise data. Data are needed to establish the global burden of HCV co-infection among PLHIV, identify the populations at risk and the key geographical regions most affected. This is essential in order to inform normative guidance and service delivery for testing and care and treatment services.
What this study adds
We estimate a mid-point of 2·3 million (IQR 1·3-4·3 million) cases of HIV/HCV co-infection globally, of whom over half -an estimated 1.3 million (IQR 0·89-1·4 million) are PWID. This equates to a global HCV co-infection prevalence of 6·2% (IQR 3·4-11·9%) among PLHIV. The greatest burden of HIV-HCV co-infection is in Eastern Europe, where an estimated 607,700 HIV infected persons are co-infected with HCV infection, followed by 429,600 in Sub-Saharan Africa. Prevalence of HCV co-infection among PLHIV is highest (82·%, 55·2-88·5%) among PWID, comparable among MSM (6·4%, IQR=3·2-10·0%) and pregnant or heterosexually exposed populations (4·0%, 1·2-8·4%), and lowest among general population samples (2.4%, IQR=0·8-5·8%). Odds of HCV infection is 6 times higher among PLHIV than HIV negative populations ranging from 1.6 times higher among the general population, 3 times higher among sex workers and 6-8 times higher among MSM, PWID and high risk populations.
Implications
Our findings clearly shows that PLHIV are at high risk of HCV infection, particularly PWID who constitute 58% of the global burden of HCV co-infections among PLHIV. Routine testing of HCV among PLHIV is needed, but especially among PWID and MSM including good linkage to care and treatment. There is also a need to improve country level monitoring of prevalence of HCV among all population groups, both HIV positive and negative groups, to define the epidemiology and to inform hepatitis C testing, prevention, care and treatment services. This will require commensurate investment in building HCV surveillance and care and treatment capacity.
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